Testing a personalized chemotherapy plan for newly diagnosed lymphoma

Plain-English translation of NCT06050694 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated August 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a smarter way to treat newly diagnosed diffuse large B-cell lymphoma (DLBCL), a type of blood cancer. You'll receive a combination chemotherapy called Pola-R-CHP for the first two cycles. Then, based on blood tests and imaging scans that measure how well the medication is working, your remaining treatment will be personalized — either continuing with chemotherapy alone, or adding a newer drug called to make the treatment stronger if your cancer shows signs of being harder to treat.

Not all patients with DLBCL respond equally to standard chemotherapy, and doctors currently have no reliable way to predict who will have trouble with standard treatment alone. This trial aims to catch patients who need more intensive therapy earlier, by using blood tests and scans to guide treatment decisions and potentially improve survival.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been newly diagnosed with diffuse large B-cell lymphoma (DLBCL) and have not received prior chemotherapy for it
you have at least one tumor that can be seen on imaging scans
your heart function is normal or near-normal, as confirmed by a heart scan or ultrasound
you are in good enough overall health to receive strong chemotherapy, as determined by your doctor
you are willing to use effective birth control during and after treatment if you could become pregnant or father a child

You likely don't qualify if…

you have lymphoma that has spread to your brain or central nervous system
you have received prior chemotherapy, rituximab (a common cancer drug), or certain other targeted antibody treatments
you have had another cancer in the past that required active treatment, except for skin cancer or other early-stage cancers that were cured
you have a history of a heart condition or low heart function that makes strong chemotherapy unsafe

What participation looks like

You will receive chemotherapy infusions every 3 weeks for 6 cycles (about 4.5 months total). After your first two cycles, you'll have blood tests and imaging scans (PET scan) to measure how your cancer is responding. Based on these results, your doctor will decide whether to continue with standard chemotherapy or add the newer medication to your remaining cycles. After treatment ends, you'll have follow-up visits with blood tests and imaging scans every 3 months to monitor your health.

AI-generated summary from trial data · Aug 5, 2026 · Not medical advice

Trial locations(3 sites)

Canada

Princess Margaret Cancer Centre, Toronto, Ontario

Jewish General Hospital, Montreal, Quebec